An expedited short-term analysis finds no increased risk for cancer in patients who took NDMA-contaminated valsartan, but uncertainty remains for colorectal and uterine cancer. The EMA weighs in.
Medscape Medical News
Original Article: Tainted Valsartan Not Linked to Cancer Risk in the Short Term